You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques

    SBC: Navidea Biopharmaceuticals, Inc.            Topic: NHLBI

    Myocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid High-Fidelity Assembly of Challenging Peptide Sequences

    SBC: VELUM INC            Topic: NIGMS

    PROJECT SUMMARY Peptide therapeutics combine high potency and selectivity with fewer side effects than traditional small moleculesThis has fueled interest in peptides filling the gap betweenbiologicsand small molecules as compounds that have the key desired properties from both the other classesWorldwide peptide drug sales surpassed $billion inof which nearly $billion was in the USAwith projected ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Discovery of TrkC agonist antibodies for hearing loss

    SBC: ZEBRA BIOLOGICS INC            Topic: NIDCD

    ! Project Summary AbstractSensori neural hearing lossSNHLis caused by several factorsincluding excessive noisedrug toxin exposure and genetic lesionsTaken togetherhearing deficits represent the number one neurological disorder worldwideDespite numerous past and ongoing clinical studies there is currently no effective therapeutic treatment for hearing loss and its associated decline in quality of l ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Multi-Modal Mechanisms of Novel Sulfated Non Anticoagulant Heparin inSickle Cell Disease Management

    SBC: VASCULAR VISION PHARMACEUTICAL CO            Topic: NHLBI

    AbstractThe pathogenesis of Sickle cell diseaseSCDcomprises a complex interplay of factors associated with vascular endothelial activationintense inflammationand increased sickle cell adhesionMicrovascular occlusion in SCD is initiated by adhesion of sickle red blood cellsRBCsto the endotheliumleading to acute painful vasoocclusive crisisVOCand the clinical morbidity in SCDTreatment strategies inc ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Dynasore Analogues for Ocular Surface Protection

    SBC: MEDCHEM PARTNERS LLC            Topic: NEI

    7. PROJECT SUMMARY Diseases of the ocular surface are among the top reasons for visits to eye care practitioners. These conditions can severely affect eyesight and quality of life. Symptoms may include blurry vision, discomfort or pain, redness and itching, and in severe cases, blindness due to corneal scarring. Many ocular surface diseases are initiated by loss of tear film homeostasis and can be ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Gene Therapy to Protect the Lung from Oxidant Stress

    SBC: LEXEO Therapeutics LLC            Topic: NHLBI

    AbstractThe focus of this proposal is the development of therapy to protect the lung with an extracellular anti oxidant defense to treat chronic obstructive pulmonary diseaseCOPDa chronic disorder in which inhaled oxidants from tobacco smokepollution and generated within the lung by activated inflammatory cells perpetuate injury to the lung epithelium and endotheliumThe LEXEO strategy is to use in ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Validation of a Cranial Neurosurgery Simulator and Assessment of Minimally Invasive Techniques

    SBC: Simulated Inanimate Models LLC            Topic: 103

    Project SummarySimulation training is unique in its ability for repetitive practice of a wide variety of scenarios and to reflect on performance without jeopardizing a patient s safetySurgical skills simulators have been successful in bridging gaps of the current training modelhoweverthese simulators fall short of offering a complete operative experienceOperative exposure with live patients still ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A recombinant matrix to improve autologous tissue grafts

    SBC: INSOMA BIO, INC.            Topic: 102

    Abstract The objective of this proposal is to validate a new regenerative tissue matrix which studies to date indicate may be possible of redefining the limits of autologous fat graftingThis objective is motivated by the currently limited surgical options available to themillion patients undergoing reconstructive plastic surgery each year to treat body disfigurement and dysfunctionA core component ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Improving ALS Diagnosis using Needle I-EMG

    SBC: Haystack Diagnostics, Inc.            Topic: 103

    PROJECT SUMMARY Needle electromyographyEMGremains the standard approach for assessing neuromuscular diseaseWhile the technique has proven to be clinically valuable over the lastyearsit has important limitationsThese include its not being sensitive to alterations in muscle composition and structureits inability to assess the contractile apparatus of muscleand its subjective nature with an inter rat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government